Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531 Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.

Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.